OBJECTIVES: To report the respiratory function of school-aged children with infantile Pompe disease (IPD) who started enzyme replacement therapy (ERT) in infancy and early childhood. STUDY DESIGN: This is a retrospective chart review of pulmonary function tests of: (a) patients with IPD 5 to 18 years of age, (b) who were not ventilator dependent, and (c) were able to perform upright and supine spirometry. Subjects were divided into a younger (5-9 years) and older cohort (10-18 years) for the analysis. Upright and supine forced vital capacity (FVC), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were analyzed. RESULTS: Fourteen patients, all cross-reactive immunologic material (CRIM)-positive, met the inclusion criteria and were included in this study. Mean upright and supine FVC were 70.3% and 64.9% predicted, respectively, in the 5- to 9-year-old cohort; and 61.5% and 52.5% predicted, respectively, in the 10- to 18-year-old group. Individual patient trends showed stability in FVC overtime in six of the 14 patients. MIPs and MEPs were consistent with inspiratory and expiratory muscle weakness in the younger and older age group but did not decline with age. CONCLUSION: Data from this cohort of CRIM-positive patients with IPD showed that ERT is able to maintain respiratory function in a subgroup of patients whereas others had a steady decline. There was a statistically significant decline in FVC from the upright to a supine position in both the younger and older age groups of CRIM-positive ERT-treated patients. Before ERT, patients with IPD were unable to maintain independent ventilation beyond the first few years of life.
OBJECTIVES: To report the respiratory function of school-aged children with infantile Pompe disease (IPD) who started enzyme replacement therapy (ERT) in infancy and early childhood. STUDY DESIGN: This is a retrospective chart review of pulmonary function tests of: (a) patients with IPD 5 to 18 years of age, (b) who were not ventilator dependent, and (c) were able to perform upright and supine spirometry. Subjects were divided into a younger (5-9 years) and older cohort (10-18 years) for the analysis. Upright and supine forced vital capacity (FVC), maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) were analyzed. RESULTS: Fourteen patients, all cross-reactive immunologic material (CRIM)-positive, met the inclusion criteria and were included in this study. Mean upright and supine FVC were 70.3% and 64.9% predicted, respectively, in the 5- to 9-year-old cohort; and 61.5% and 52.5% predicted, respectively, in the 10- to 18-year-old group. Individual patient trends showed stability in FVC overtime in six of the 14 patients. MIPs and MEPs were consistent with inspiratory and expiratory muscle weakness in the younger and older age group but did not decline with age. CONCLUSION: Data from this cohort of CRIM-positive patients with IPD showed that ERT is able to maintain respiratory function in a subgroup of patients whereas others had a steady decline. There was a statistically significant decline in FVC from the upright to a supine position in both the younger and older age groups of CRIM-positive ERT-treated patients. Before ERT, patients with IPD were unable to maintain independent ventilation beyond the first few years of life.
Authors: P Laforêt; K Laloui; B Granger; D Hamroun; N Taouagh; J-Y Hogrel; D Orlikowski; F Bouhour; A Lacour; E Salort-Campana; I Penisson-Besnier; S Sacconi; F Zagnoli; F Chapon; B Eymard; C Desnuelle; J Pouget Journal: Rev Neurol (Paris) Date: 2013-09-03 Impact factor: 2.607
Authors: Tammy L Yanovitch; Suhrad G Banugaria; Alan D Proia; Priya S Kishnani Journal: J Pediatr Ophthalmol Strabismus Date: 2010-01-21 Impact factor: 1.402
Authors: Hannerieke M P van den Hout; Wim Hop; Otto P van Diggelen; Jan A M Smeitink; G Peter A Smit; Bwee-Tien T Poll-The; Henk D Bakker; M Christa B Loonen; Johannis B C de Klerk; Arnold J J Reuser; Ans T van der Ploeg Journal: Pediatrics Date: 2003-08 Impact factor: 7.124
Authors: Lara R DeRuisseau; David D Fuller; Kai Qiu; Keith C DeRuisseau; William H Donnelly; Cathryn Mah; Paul J Reier; Barry J Byrne Journal: Proc Natl Acad Sci U S A Date: 2009-05-27 Impact factor: 11.205
Authors: Juna M de Vries; Nadine A M E van der Beek; Wim C J Hop; Francois P J Karstens; John H Wokke; Marianne de Visser; Baziel G M van Engelen; Jan B M Kuks; Anneke J van der Kooi; Nicolette C Notermans; Catharina G Faber; Jan J G M Verschuuren; Michelle E Kruijshaar; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg Journal: Orphanet J Rare Dis Date: 2012-09-26 Impact factor: 4.123
Authors: Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson Journal: Genet Med Date: 2006-05 Impact factor: 8.822
Authors: C M van Gelder; E Poelman; I Plug; M Hoogeveen-Westerveld; N A M E van der Beek; A J J Reuser; A T van der Ploeg Journal: J Inherit Metab Dis Date: 2016-01-14 Impact factor: 4.982
Authors: Anna F Fusco; Angela L McCall; Justin S Dhindsa; Lucy Zheng; Aidan Bailey; Amanda F Kahn; Mai K ElMallah Journal: Int J Mol Sci Date: 2020-03-24 Impact factor: 5.923